Mantle Cell Lymphoma
Mantle Cell Lymphoma
The latest news, research, and perspectives in mantle cell lymphoma (MCL). In MCL, a malignant B lymphocyte in the outer edge, or mantle zone, of a lymph node follicle grows uncontrollably, resulting in the accumulation of lymphoma cells.
Advertisement
Xu Ji, PhD, MSPHVideo Insights | January 3, 2025
A database study has identified an association between disease stage at lymphoma diagnosis and time of Medicaid enrollment.
Nichole TuckerMantle Cell Lymphoma | December 20, 2024
Updated results from the phase 3 ECHO trial were presented at ASH 2024.
Julie GouldMantle Cell Lymphoma | December 20, 2024
Future research must focus on developing more effective therapies to address the unmet needs of this high-risk MCL.
Nichole TuckerFollicular Lymphoma | December 12, 2024
Results from the phase 1 ENABLE-1 study show complete responses comparable to commercial CAR Ts in B-cell NHL.
Nichole TuckerChronic Lymphocytic Leukemia | December 12, 2024
CTX112, a next-generation allogeneic CRISPR-Cas9–engineered showing encouraging results in B-cell malignancies.
Andrew MorenoMeeting News | December 9, 2024
The approach demonstrated safety and produced response in B-ALL, DLBCL, follicular lymphoma, and MCL.
Advertisement
Melissa BadamoTransplantation & Cellular Therapy | December 8, 2024
Acalabrutinib, umbralisib, and ublituximab treatment is effective in patients with de novo MCL, with a 100% CR rate.
Andrew MorenoMantle Cell Lymphoma | December 2, 2024
A team of researchers investigated this mechanism of therapy resistance specifically to CD19-directed CAR T-cell therapy.
Andrew MorenoPrint | October 2, 2024
The anti-CD19 autologous CAR-T-cell therapy was approved for use in adults with relapsed or refractory disease.
Andrew MorenoMantle Cell Lymphoma | August 23, 2024
The results from a phase I seamless design study are relevant especially to older patients and those with high-risk disease.
Melissa BadamoMantle Cell Lymphoma | July 31, 2024
The study compared treatment response based on prior systemic lines of therapy and prior BTK inhibition in patients with MCL.
Tycel Phillips, MDMantle Cell Lymphoma | June 25, 2024
The 15-month PFS was approximately 33% for patients who were BTK exposed and over 50% for patients who were BTK naïve.
Yucai Wang, MD, PhDMantle Cell Lymphoma | June 14, 2024
After five and a half years of follow-up, rituximab maintenance significantly improved survival outcomes.
Melissa BadamoMantle Cell Lymphoma | May 30, 2024
Granted under FDA Priority Review, the approval is based on results from the MCL cohort of the TRANSCEND NHL 001 study.
Kami Maddocks, MDMantle Cell Lymphoma | April 3, 2024
Dr. Maddocks hopes that current trials will help us “spring forward” into a chemotherapy-free approach to treating MCL.
Patrick DalyMantle Cell Lymphoma | April 2, 2024
Liso-cel received regulatory acceptances from the US FDA and the Ministry of Health, Labour and Welfare in Japan for FL.
Blood Cancer TalksBlood Cancer Talks | March 20, 2024
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Melissa BadamoMantle Cell Lymphoma | December 18, 2023
Narazaciclib plus ibrutinib regulated signatures associated with DNA repair, P53 signaling, and glycolytic activity.
Michael Wang, MDMantle Cell Lymphoma | December 22, 2023
Progression-free survival was significantly prolonged with the combination compared with a placebo.
Melissa BadamoMantle Cell Lymphoma | December 15, 2023
The trial established the recommended phase II dose of acalabrutinib, venetoclax, and obinutuzumab.
Advertisement
Advertisement
Editorial Board